CVC  Alexandria Real Estate Equities

http://www.are.com/





     Office Locations:

400 Technology Square, Suite 101
Cambridge, MA 02139
Phone: 508-755-4249

Get all office locations for this firm with a National Database subscription or New York Database subscription.
 

Stages:

  • Early
  • Seed


 

Industries:

  • Energy & Clean Tech
  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Alexandria Equities, LLC is the strategic investment entity of Alexandria Real Estate Equities, Inc. (ARE: NYSE). Alexandria Equities provides capital to the broad and diverse life science sector. Since 1994, Alexandria Real Estate has created first-in-class life science clusters that foster innovative and collaborative environments in key locations immediately proximate to leading research institutions. Alexandria's diverse tenant base includes internationally renowned academic and medical institutions, multinational pharmaceutical companies, leading private and public biotechnology entities, non-profit institutions, government agencies, medical device companies, biofuels companies, research tools and service companies, and venture capitalists.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Amanda Cashin PhD Senior Vice President
    Andres Gavinet Chief Accounting Officer
    Daniel J. Ryan Executive VP and Regional Market Director
    Dean A. Shigenaga Chief Financial Officer & Treasurer
    Jennifer J. Banks Executive Vice President

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      08/13/2018


      Magnolia Neurosciences


      NY


      $31,000,000


      Series A


      06/28/2018


      Precision BioSciences


      NC


      $110,000,000


      Series B


      06/13/2018


      StrideBio


      NC


      $15,700,000


      Series A


      06/08/2018


      Metacrine


      CA


      $65,000,000


      Series C


      04/27/2018


      Proniras


      WA


      undisclosed


      


      03/21/2018


      TCR2 Therapeutics


      MA


      $125,000,000


      Series B


      02/28/2018


      Quentis Therapeutics


      NY


      $48,000,000


      Series A


      02/02/2018


      Moderna Therapeutics


      MA


      $500,000,000


      


      01/03/2018


      Expansion Therapeutics


      CA


      $55,300,000


      Series A


      12/06/2017


      Obsidian Therapeutics


      MA


      $49,500,000


      Series A


      10/02/2017


      KSQ Therapeutics


      MA


      $76,000,000


      


      09/18/2017


      LifeMine Therapeutics


      MA


      $55,000,000


      Series A


      08/23/2017


      GNS Healthcare


      MA


      $6,000,000


      


     

    Portfolio companies include:


      Adaptive Biotechnologies
        web link


      Agrivida
        web link


      Antiva Biosciences
        web link


      ApoGen Biotechnologies
        web link


      Arsanis
        web link


      Atara Biotherapeutics
        web link


      Aura Biosciences
        web link


      Avidity Biosciences
        web link


      Benson Hill Biosystems


      Biological Dynamics
        web link


      BlackThorn Therapeutics
        web link


      Calimmune
        web link


      Concert Pharmaceuticals
        web link


      Cydan
        web link


      Effector Therapeutics
        web link


      eGenesis
        web link


      Expansion Therapeutics
        web link


      Flex Pharma
        web link


      Frequency Therapeutics
        web link


      GNS Healthcare
        web link


      Kinestral Technologies
        web link


      KSQ Therapeutics
        web link


      LifeMine Therapeutics
        web link


      Lodo Therapeutics
        web link


      Magnolia Neurosciences
        web link


      Metacrine
        web link


      Moderna Therapeutics
        web link


      Molecular Assemblies
        web link


      Obsidian Therapeutics
        web link


      OncoResponse
        web link


      Precision BioSciences
        web link


      Proniras
        web link


      Quentis Therapeutics
        web link


      RGenix
        web link


      Seres Health
        web link


      StrideBio
        web link


      Synthego
        web link


      Syros Pharmaceuticals
        web link


      TCR2 Therapeutics
        web link


      Theraclone Sciences
        web link


      Visterra
        web link


      Vtesse
        web link


      WellDoc
        web link


      Yumanity Therapeutics
        web link


     

    Recent News: